SCHEMBL3308095

SCHEMBL3308095

FC(F)(F)c1ccc(-c2ccc3scnc3c2)cn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 3/20 0.53
PIK3CD O00329 2/20 0.53
PI4KB Q9UBF8 2/20 0.53
PIK3CB P42338 1/20 0.53
PI4KA P42356 1/20 0.53
PIK3CG P48736 1/20 0.53
TRPV4 Q9HBA0 1/20 0.40
RIPK2 O43353 2/20 0.38
KDR P35968 2/20 0.38
TGFBR1 P36897 2/20 0.38
EGFR P00533 1/20 0.38
DYRK1A Q13627 1/20 0.38
PDE10A Q9Y233 1/20 0.38
FFAR1 O14842 1/20 0.38
ALOX5AP P20292 1/20 0.37
FEN1 P39748 1/20 0.37
AKT1 P31749 1/20 0.37
MTOR P42345 1/20 0.37
CASP3 P42574 1/20 0.37
LCK P06239 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28048502 0.80 ALDH1A1 (0.54) PIK3CDRIPK2KDRTGFBR1EGFR
SCHEMBL1854129 0.80 CYP2A6 (0.45) PIK3CAPIK3CDRIPK2KDRTGFBR1
SCHEMBL3305165 0.77 CYP11B2 (0.47) PIK3CDPIK3CBRIPK2KDRTGFBR1
SCHEMBL1851823 0.76 KIF11 (0.49) ALOX5APFEN1
SCHEMBL3307500 0.76 MPL (0.48) RIPK2KDRTGFBR1EGFRDYRK1A
SCHEMBL1852264 0.75 TGFBR1 (0.46) PIK3CDRIPK2KDRTGFBR1EGFR
SCHEMBL3307688 0.74 RXRA (0.42) PIK3CDRIPK2KDRTGFBR1EGFR
SCHEMBL3308104 0.74 KIF11 (0.43) PIK3CDRIPK2KDRTGFBR1FFAR1
SCHEMBL3305147 0.74 PIK3CD (0.42) PIK3CAPIK3CDRIPK2KDRTGFBR1
SCHEMBL3309985 0.73 APP (0.48) PIK3CDRIPK2KDRTGFBR1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420052-B2 Imaging agents useful for identifying AD pathology SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2013-04-16 US disclosed
US-8420052-B2 Imaging agents useful for identifying AD pathology SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2013-04-16 US disclosed
US-8420052-B2 Imaging agents useful for identifying AD pathology SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2013-04-16 US disclosed
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology SIEMENS MEDICAL SOLUTIONS USA, INC. 2010-04-22 US disclosed
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology SIEMENS MEDICAL SOLUTIONS USA, INC. 2010-04-22 US disclosed
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology SIEMENS MEDICAL SOLUTIONS USA, INC. 2010-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology APP, APBA1, PYGB PIK3CA 4138/4885PIK3CD 4367/4885PI4KB 3436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.